Article info

Download PDFPDF
Case based discussion
Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage

Authors

  1. Correspondence to Dr Nadia Nathan, Pediatric Pulmonology and Reference centre for rare lung diseases, AP-HP, Trousseau Hospital, Sorbonne University, Paris 75012, France; nadia.nathan{at}aphp.fr
View Full Text

Citation

Frémond M, Legendre M, Fayon M, et al
Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage

Publication history

  • Received July 29, 2019
  • Revised October 1, 2019
  • Accepted October 4, 2019
  • First published October 30, 2019.
Online issue publication 
December 13, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.